Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome

Milos Jesenak; Maria Zelieskova; Miroslav Repko; Peter Banovcin

doi:10.5114/ceji.2020.101269

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

3/2020
vol. 45

Send email

Copy url:

abstract:

Case report

Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome

Milos Jesenak

¹

,

Maria Zelieskova

¹

,

Miroslav Repko

²

,

Peter Banovcin

¹

Department of Pediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia
Department of Pediatrics, Hospital in Poprad, Slovakia

Cent Eur J Immunol 2020; 45 (3): 361-363

DOI: https://doi.org/10.5114/ceji.2020.101269

Online publish date: 2020/11/01

View full text Get citation

PlumX metrics:

DiGeorge syndrome (DGS) is a primary immunodeficiency disease characterized by multiple clinical features, including congenital heart defects, typical facial appearance, hypocalcemia, and immunodeficiency associated to thymic hypoplasia. A subset of patients with DGS may also have contemporary allergic diseases, possibly in the context of T cell dysregulation. Our work presents an unusual case of DGS in coincidence with severe allergic asthma successfully treated by humanized monoclonal anti-IgE antibody, omalizumab. Biological therapy with omalizumab is indicated as an add-on treatment for poorly controlled asthma in patients with severe persistent allergic asthma aged 6 years and above, who meet strict criteria. While data available from clinical trials suggest that omalizumab is generally well-tolerated, a little is known about its efficacy and tolerability in the context of underlying immunodeficiency. We reported for the first time that omalizumab could be safely effective in treatment of severe allergic asthma in patients with DGS, without modification of immunological parameters.

keywords:

Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome

Milos Jesenak 1 , Maria Zelieskova 1 , Miroslav Repko 2 , Peter Banovcin 1

immunodeficiency, DiGeorge syndrome, omalizumab, severe allergic asthma, immune dysregulation

Milos Jesenak

¹

,

Maria Zelieskova

¹

,

Miroslav Repko

²

,

Peter Banovcin

¹